Where Apellis Pharmaceuticals Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Apellis Pharmaceuticals (NASDAQ:APLS) within the last quarter, with the majority being bullish. According to 17 analysts offering 12-month price targets in the last 3 months, Apellis Pharmaceuticals has an average price target of $76.71, a 24.74% decrease from the previous average price target of $101.92.
August 04, 2023 | 2:36 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts' ratings for Apellis Pharmaceuticals are mostly bullish, but the average 12-month price target has decreased by 24.74% to $76.71.
The majority of analysts are bullish on Apellis Pharmaceuticals, indicating a positive outlook. However, the decrease in the average 12-month price target suggests that they expect the stock price to decrease in the short term. This could lead to a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100